Emodan Caution For Usage

Precaution for Administration: Ondansetron injection should not be administered in the same syringe or infusion as any other medication.
Ondansetron injection should not be autoclaved.
Ondansetron injection should only be admixed with those infusion solutions which are recommended: Normal Saline (0.5% w/v Sodium chloride Intravenous infusion); 5% w/v Glucose intravenous infusion; 10 % w/v Mannitol intravenous infusion; Ringers intravenous infusion; Potassium chloride 0.3 % w/v and Sodium chloride 0.9 % w/v intravenous infusion; Potassium chloride 0.3 % w/v and Glucose 5 % w/v intravenous infusion.
Use immediately after dilution or store at 2-8℃ for no more than 24 hours.
Compatibility studies have been undertaken in polyvinyl chloride infusion bags and polyvinyl chloride administration sets. It is considered that adequate stability would also be conferred by the use of polyethylene infusion bags or Type 1 glass bottles. Dilutions of Ondansetron in sodium chloride 0.9 % w/v or in glucose 5 % w/v have been demonstrated to be stable in polypropylene syringes. It is considered that Ondansetron injection diluted with other compatible infusion fluids would be stable in polypropylene syringes.
Ondansetron may be administered by intravenous infusion at 1 mg/hour, e.g. from an infusion bag or syringe pump.
The following drugs may be administered via the Y-site of the Ondansetron infusion set for Ondansetron concentrations of 16 to 160 micrograms/mL (e.g. 8 mg/500 mL~8 mg/50 mL respectively): Cisplatin: Concentrations up to 0.48 mg/mL (e.g. 240 mg in 500 mL) administered over one to eight hours.
5-Fluorouracil: Concentrations up to 0.8 mg/mL (e.g. 2.4 g in 3 liters or 400 mg in 500 mL) administered at a rate of at least 20 mL per hour (500 ml per 24 hours). Higher concentrations of 5-fluorouracil may cause precipitation of Ondansetron. The 5-fluorouracil infusion may contain up to 0.045 % w/v magnesium chloride in addition to other excipients shown to be compatible.
Carboplatin: Concentrations in the range 0.18 mg/mL to 9.9 mg/mL (e.g. 90 mg in 500 mg and to 990 mg in 100 mL), administered over ten minutes to one hour.
Etoposide: Concentrations in the range 0.14 mg/mL to 0.25 mg/mL (e.g. 72 mg in 500 mL and 250 mg in 1 liter), administered over thirty minutes to one hour.
Ceftazidime: Doses in range 250 mg to 2000 mg reconstituted with Water for injections BP as recommended by the manufacturer (e.g. 2.5 mL for 250 mg and 10 mL for 2 g ceftazidime) and given as an intravenous bolus injection over approximately five minutes.
Cyclophosphamide: Doses in the range 100 mg to 1 g, reconstituted with Water for injections BP, 5 mL per 100 mg cyclophosphamide, as recommended by the manufacturer and given as an intravenous bolus injection over approximately five minutes.
Doxorubicin: Doses in the range 10-100 mg reconstituted with Water for injections BP, 5 mL per 10 mg doxorubicin, as recommended by the manufacturer and given as an intravenous bolus injection over approximately five minutes.
Dexamethasone: Dexamethasone sodium phosphate 20 mg may be administered as a slow intravenous injection over 2-5 minutes via the Y-site of an infusion set delivering 8 or 32 mg of Ondansetron diluted in 50-100 mL of a compatible infusion fluid over approximately 15 minutes.
Compatibility between dexamethasone sodium phosphate and Ondansetron has been demonstrated supporting administration of these drugs through the same infusion set resulting in concentrations in line of 32 microgram-2.5 mg/mL for dexamethasone sodium phosphate and 8 microgram-1 g/mL for Ondansetron.